CDEK
← All drugs Report issue

piperine

Small moleculeexperimental

Piperine, possibly along with its isomer chavicine, is the compound responsible for the pungency of black pepper and long pepper via activation of TRPV1. It has been used in some forms of traditional medicine. — Wikipedia

Clinical trial activity

18 trials · 22 clinical orgs · 0 marketing orgs

Phase 1
5
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Nov 1, 2004 (NCT00113841)

Timeline

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

2020s

  1. Jan 1, 2021

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

O=C(/C=C/C=C/c1ccc2c(c1)OCO2)N1CCCCC1
Mol. weight
285.34 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • ((1-5-(1,3)-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)piperidine
  • (1-(5-(1,3)-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)piperidine
  • 1-piperoylpiperidine
  • bioperine
  • bioperine
  • bioperine
  • bioprine
  • piperine
  • piperine
  • piperine
  • piperine
  • piperine
  • piperine, (e,e)-isomer
  • piperine, (e,z)-isomer
  • piperine, (z,e)-isomer
  • piperine, (z,z)-isomer

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07149961N/AFeb 5, 2025Diponegoro University
NCT06063486Phase 2Nov 20, 2023National Cancer Institute (NCI), University of Southern California
NCT06242535Early Phase 1 (Phase 1)Jul 27, 2023Buck Institute for Research on Aging, Hoskinson Health and Wellness Clinic, University of Wyoming
NCT06080841N/AApr 19, 2023National Institute of Cancerología, Sabinsa Corporation
NCT05083546Phase 1/Phase 2 (Phase 2)Apr 1, 2022University of California, San Francisco
NCT04731844Phase 2Dec 1, 2021University of Rochester
NCT05735626N/AJul 1, 2021Hospital de Mataró, Universidad Carlos III Madrid
NCT04741620N/AJan 17, 2019Hospital de Mataró
NCT03475017Phase 3Feb 22, 2018Fluminense Federal University
NCT03066791N/ANov 30, 2016University of California, Davis
NCT02598726Phase 1Mar 1, 2016Mayo Clinic, National Cancer Institute (NCI)
NCT01893424Phase 1Aug 1, 2013Hebrew University
NCT01383694Phase 1/Phase 2 (Phase 2)Jun 1, 2011Hospital de Mataró
NCT01324089N/AMar 1, 2011National Cancer Institute (NCI), National Institutes of Health (NIH), University of Wisconsin
NCT01288859N/ADec 31, 2010University of Naples Frederico II
NCT00595582N/AMay 1, 2005Louisiana State University
NCT01514266N/AApr 1, 2005Baylor University, University of Texas at Houston
NCT00113841N/ANov 1, 2004University of Texas at Houston
Showing 18 of 18 trials
Page 1 / 1

Organizations

Research & Development (22)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Hospital de MataróAcademic/Hospital3322011
National Cancer Institute (NCI)Government3032011
University of Texas at HoustonAcademic/Hospital2112004
Baylor UniversityAcademic/Hospital1112005
Buck Institute for Research on AgingAcademic/Hospital1012023
Diponegoro UniversityAcademic/Hospital1112025
Fluminense Federal UniversityAcademic/Hospital1112018
Hebrew UniversityAcademic/Hospital1112013
Hoskinson Health and Wellness ClinicAcademic/Hospital1112023
Louisiana State UniversityAcademic/Hospital1112005
Mayo ClinicAcademic/Hospital1112016
National Institute of CancerologíaAcademic/Hospital1112023
National Institutes of Health (NIH)Government1012011
Sabinsa CorporationFor profit1012023
Universidad Carlos III MadridAcademic/Hospital1012021
University of California, DavisAcademic/Hospital1112016
University of California, San FranciscoAcademic/Hospital1112022
University of Naples Frederico IIAcademic/Hospital1112010
University of RochesterAcademic/Hospital1112021
University of Southern CaliforniaAcademic/Hospital1112023
22 organizations
Page 1 / 2